

August 14, 2023



## **Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit**

SAN JOSE, Calif., Aug. 14, 2023 /PRNewswire/ -- [Anixa Biosciences, Inc.](#) ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Anixa's Chief Development Officer, has been invited to present at the 8<sup>th</sup> Annual CAR-TCR Summit being held from August 29 – September 1, 2023 in Boston, MA.

The 8th Annual CAR-TCR Summit is the world's pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types. During this three-day event over one thousand attendees from over three hundred companies will come together to explore discovery through commercialization to deliver safe, effective and commercially viable CAR and TCR therapies.

Entitled "Developing a CAR-T for Ovarian Cancer and Other Solid Tumors," the presentation will focus on the opportunities and challenges of CAR-T for solid tumors, routes of administration besides intravenous infusions and details of the ovarian cancer CAR-T therapy clinical trial (NCT05316129) under the direction of Dr. Robert Wenham at Moffitt Cancer Center and in collaboration with Anixa. This trial, a Phase I clinical trial of autologous T cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer, will evaluate intraperitoneal and intravenous administration of the CAR-T and the role of lymphodepletion. The study commenced July of 2022 and is in progress.

Dr. Garzone will also be hosting a roundtable discussion titled, "Impacting CAR-T Efficacy with Pre-Conditioning Regimens." Topics covered during this roundtable will include discussion on differences between lymphodepletion regimens and outcomes for liquid and solid tumors, impact of lymphodepletion intensity on CAR-T cell therapy, and how to achieve optimal balance between efficacy and safety.

**About Anixa Biosciences, Inc.**

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program that uses a novel type of CAR-T known as chimeric endocrine receptor T cell (CER-T) technology, and is being developed in collaboration with Moffitt Cancer Center. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit [www.anixa.com](http://www.anixa.com) or follow Anixa on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

### **Forward-Looking Statements**

Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

### **Contacts:**

Stephen Kilmer  
Investor Relations  
[skilmer@anixa.com](mailto:skilmer@anixa.com)  
646-274-3580

Mike Catelani  
President, COO & CFO  
[mcatelani@anixa.com](mailto:mcatelani@anixa.com)  
408-708-9808

View original content to download multimedia <https://www.prnewswire.com/news-releases/anixa-biosciences-announces-invited-presentation-on-ovarian-cancer-car-t-therapy-at-the-8th-annual-car-tcr-summit-301899176.html>

SOURCE Anixa Biosciences, Inc.